Denali Therapeutics Inc

DNLINASDAQ · USD
18.74USD0.00 (-0.80%)
137

Denali Therapeutics Inc (DNLI) Implied Volatility Current

DNLI's 30 day implied volatility is 104.30%, with an IV Rank of 91.27%. This is a high IV Rank versus the past year, meaning Denali Therapeutics Inc options are relatively expensive and currently favor sellers. DNLI's 30 day historical volatility sits at 47.59%, which means implied volatility is running 56.71 points above historical volatility, as of Nov 13, 2026.

Read more

Tracking DNLI implied volatility helps you spot when Denali Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When DNLI IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor DNLI implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking DNLI IV rank helps you see whether DNLI's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.

Implied Volatility

IV Rank
91.27%IV Rank
High

IV is highly elevated. Premiums are expensive, strongly favoring sellers.

Implied Volatility (30d)104.30%

IV Rank91.27%

Historical Volatility (30d)47.59%

IV Minus HV+56.71%

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →